Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 2014-2024
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2014
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Patient-screening flowchart. NCRT: Neoadjuvant chemoradiotherapy; TME: Tumor microenvironment; RC: Rectal cancer; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Overall survival curves and disease-free survival curves stratified by pre-neoadjuvant chemoradiotherapy carcinoembryonic antigen levels. A: Overall survival curves stratified by pre-neoadjuvant chemoradiotherapy carcinoembryonic antigen (CEA) levels; B: Disease-free survival curves stratified by pre-neoadjuvant chemoradiotherapy CEA levels. NCRT: Neoadjuvant chemoradiotherapy; CEA: Carcinoembryonic antigen; OS: Overall survival; DFS: Disease-free survival.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Overall survival curves and disease-free survival curves stratified by pre-neoadjuvant chemoradiotherapy cancer antigen 19-9 levels. A: Overall survival curves stratified by pre-neoadjuvant chemoradiotherapy cancer antigen 19-9 (CA19-9) levels; B: Disease-free survival curves stratified by pre-neoadjuvant chemoradiotherapy CA19-9 levels. CA19-9: Cancer antigen 19-9; OS: Overall survival; DFS: Disease-free survival.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Overall survival curves and disease-free survival curves stratified by novel serum tumor biomarker scores. A: Overall survival curves stratified by novel serum tumor biomarker scores; B: Disease-free survival curves stratified by novel serum tumor biomarker scores. NSTB: Novel serum tumor biomarker; OS: Overall survival; DFS: Disease-free survival.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Predictive nomogram predicting overall survival in clinical stage II/III RC patients undergoing NCRT. PTNM: Pathological tumor-node- metastasis; NSTB: Novel serum tumor biomarker; OS: Overall survival.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Predictive nomogram predicting disease-free survival in clinical stage II/III RC patients undergoing NCRT. PTNM: Pathological tumor-node-metastasis; NSTB: Novel serum tumor biomarker; DFS: Disease-free survival.